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Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical
practice and is associated with a higher risk of thromboembolic events. CHA2DS2VASc
score enables  identification of  those patients  with AF who will  most  benefit  from
anticoagulation therapy and low-risk patients with AF who do not need any antith‐
rombotic therapy. Antithrombotic drugs especially oral anticoagulants (OACs) are the
mainstay  of  therapy  to  prevent  stroke  in  patients  with  AF.  Although  vitamin  K
antagonists  (VKAs)  were  the  only  available  drugs  for  decades,  numerous  non–
vitamin K antagonist oral anticoagulants (NOACs) have been developed and market‐
ed for stroke prevention in recent years. The risk of stroke was reported to decline up
to 68 % with OAC therapy, associated with good anticoagulation control with VKAs,
assessed by time in therapeutic range (TTR). In low TTR values, VKAs were found to
be  associated  with  severe  complications,  and a  minimum TTR of  58 % should  be
achieved to expect a net benefit from being on OAC therapy. Narrow therapeutic index,
drug-drug interactions, and the need for close monitoring are the main disadvantages
of VKAs, and management of patients have dramatically improved after the introduc‐
tion of NOACs. NOACs have a more predictable anticoagulant affect which allows a
fixed-dose regimen. The efficacy and safety of NOACs have been shown not only in
large randomized controlled clinical trials but also in observational studies. The main
advantages  of  NOACS  such  as  “fixed-dose  regimen”  and  “no  need  for  regular
anticoagulant therapy monitoring” may also be the Achilles heel of the use of these
agents. Fixed-dose regimen may not be appropriate for elderly, for patients with chronic
kidney disease, and for patients using interacting drugs. Adherence to NOAC therapy
is another concern as it may be as low as 50 % in the chronic use of cardiovascular drugs,
especially if the drug has no apparent affect to the patient. Thus, appropriate use of
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OACs among non-valvular AF (NVAF) patients is essential for stroke prophylaxis. We
intended to review the use of OAC therapy among (NVAF) patients.
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1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and
is associated with a higher risk of thromboembolic events [1]. The most devastating complica‐
tion of AF is ischemic stroke. AF is the most frequent cause of cardioembolic stroke and nearly
20 % of all stroke events. Cardioembolic stroke has a greater morbidity and mortality compar‐
ing other stroke subtypes. Nevertheless, oral anticoagulant (OAC) drugs offer an effective stroke
prevention strategy [2]. Recent guidelines recommend to start an OAC drug for patients who
have AF and high risk of stroke assessed by stroke risk schemes [3]. The most recommended
risk scheme is known by the acronym CHA2DS2VASc (congestive heart failure, hypertension,
age ≥75, diabetes, stroke history, vascular disease, ages 65–74, and sex), and patients with a
score ≥2 should be anticoagulated. The discovery and development of anticoagulants are some
of the most interesting in pharmaceutical history and started with the discovery of heparin in
1916 (Figure 1). Studies on anticoagulant drugs led to the commercialization of dicoumarol in
1941, and efforts to develop an effective rodenticide resulted in synthesis of warfarin (Wiscon‐
sin Alumni Research Foundation), which was approved for medical use in 1954. For decades,
vitamin K antagonists (VKAs) were the only available oral anticoagulants. The risk of stroke
was reported to decline up to 68 % with OAC therapy, associated with good anticoagulation
control with VKAs, assessed by time in therapeutic range (TTR). In low TTR values VKAs were
found to be associated with severe complications, and a minimum TTR of 58 % should be achieved
to expect a net benefit from being on OAC therapy [4]. The use of VKAs can also be challeng‐
ing due to narrow therapeutic index, drug-drug interactions, and the need for close monitor‐
ing. Over the last years, non–vitamin K antagonist oral anticoagulants (NOACs) have been
developed, including direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivarox‐
Figure 1. Developmental history of anticoagulants.
Anticoagulation Therapy130
aban, apixaban, and edoxaban) which have a more predictable anticoagulant affect allowing a
fixed-dose regimen. Their therapeutic use for prevention of cardioembolic complications was
validated in large phase III trials, demonstrating their non-inferiority and even superiority, in
some cases, to warfarin [5–8]. Therefore, the use of NOACs is currently recommended by
guidelines,  along with  VKAs,  for  stroke  prevention  in  patients  with  non-valvular  atrial
fibrillation (NVAF). The risk of hemorrhage should also be assessed prior to starting an OAC
drug. One of the validated risk scores is hypertension, renal or liver failure, stroke history,
bleeding history, labile international normalized ratio (INR), age > 65 years, drugs predispos‐
ing to bleeding, and alcohol use (HAS-BLED). Bleeding risk assessment with HAS-BLED should
not be used as an excuse not to prescribe OAC but rather to highlight those patients in whom
caution with such treatment and regular review is warranted. Both VKA and NOACs have
specific targets in the coagulation cascade (Figure 2). The INR is widely used for the measure‐
ment of anticoagulant effect of VKAs. However, the anticoagulant effect of NOACs cannot be
measured with routine coagulation assays. While activated partial thromboplastin time (aPTT)
is elevated in patients taking dabigatran and edoxaban, it is not correlated with the dose of the
drug. Ecarin-clotting time (ECT), thrombin time (TT), and dilute thrombin time (dTT) assays
Figure 2. The coagulation cascade. VKA, vitamin K antagonist.
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might be used for dabigatran’s anticoagulant effect and anti-factor Xa assays for rivaroxaban
and apixaban. However, these assays are not commercially available that restricts their use in
most institutions. Although NOACs have clear advantages comparing warfarin, it may not be
convenient for some patients. They were not studied in patients with severe renal failure
(estimated glomerular filtration rate (GFR) <30 mL/min), and a dose reduction is recommend‐
ed for patients with moderate renal failure (GFR: 30–50 mL/min). The use of NOACs in patients
with mechanical heart valves is contraindicated. The RE-ALIGN (randomized, phase II study
to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart
valve replacement) study showed that dabigatran was neither effective nor safe in patients with
mechanical heart valves [8]. However, it was safe and effective in other types of valvular diseases
such as mitral regurgitation, aortic regurgitation, aortic stenosis, tricuspid regurgitation, and
mild mitral stenosis [9]. Thus the term “valvular AF” defines patients with mechanical heart
valves and patients with mitral stenosis (mostly rheumatic) [10]. In this chapter, we will review
the clinical use, real-world data, and reversal of anticoagulant effect of NOACs for stroke
prevention in patients with NVAF as well as discuss the limitations of the new agents.
2. Direct thrombin inhibitors
Direct thrombin inhibitors act by inhibiting thrombin which converts fibrinogen to fibrin and
activates platelets (Figure 2). Ximelagatran was the first-studied direct thrombin inhibitor for
stroke prophylaxis in NVAF patients, but it was withdrawn from market because of safety
concerns about hepatotoxicity.
2.1. Dabigatran
Dabigatran was the first-introduced NOAC into clinical practice. It was predominantly
eliminated by kidneys; thus, a dose reduction was proposed for patients with renal failure [3].
The European Medical Agency (EMA) has approved two doses (110 and 150 mg) of dabigatran
with a recommendation of dose reduction in older patients with renal failure. However, Food
and Drug Administration (FDA) did not approve the 110 mg bid and approved 75 mg bid for
patients with renal failure. FDA recommended the higher dose (150 mg bid) for most of the
patients. Though it remains a controversial issue, FDA did not change its recommendations
after a mini-sentinel [11]; however, a post hoc analysis of RE-LY trial showed better outcomes
if European label was used [12]. Nevertheless, with the available data for both doses, dabiga‐
tran is an attractive alternative to warfarin in patients with NVAF. A meta-analysis of real-
world data also showed similar efficacy compared to warfarin with less intracranial bleeding
[13]. The authors concluded dabigatran should be used cautiously in older patients with a
history of gastrointestinal bleeding.
Although dabigatran was well tolerated, prevalence of dyspepsia was increased compared to
warfarin (11.8 % with 110 mg bid, 11.3 % with 150 mg bid, 5.8 % with warfarin). This side effect
has been attributed to tartaric acid component in dabigatran etexilate capsule [14]. Although
dabigatran has lower rates of drug-drug interaction, it has significant interaction with p-
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glycoprotein inhibitors (e.g., ketoconazole, amiodarone, verapamil) and inducers (rifampin).
A dose reduction was proposed for patients taking concomitant verapamil.
3. Factor Xa inhibitors
Factor Xa has an important role in the coagulation cascade (Figure 2). Currently there are three
approved factor Xa inhibitors—rivaroxaban, apixaban, and edoxaban—and one under
investigation betrixaban.
3.1. Rivaroxaban
Rivaroxaban was the first-approved factor Xa inhibitor for stroke prophylaxis in NVAF.
Rivaroxaban 15 mg od was given for patients with creatinine clearance 30–50 mL/min. It was
found as effective as warfarin for stroke or systemic embolism prevention without an increase
in major bleeding [7]. In addition, it was associated with less intracranial bleeding. Real-world
analysis of rivaroxaban also revealed comparable bleeding rates with phase III trial with a
significant heterogeneity in bleeding rates across studies [15]. A real-world analysis of
rivaroxaban showed similar results comparing warfarin for safety and efficacy; however,
venous thromboembolism (VTE) events were fewer in rivaroxaban patients [16]. Another real-
world analysis showed that rivaroxaban may even be better in terms of hemorrhagic compli‐
cations or at least as safe as warfarin [17]. Coleman et al. showed that rivaroxaban may be
better for stroke prophylaxis in a German medical record study [18]. In conclusion, rivaroxaban
was shown to be as effective and safe as warfarin in real-world data.
3.2. Apixaban
Apixaban is a factor Xa inhibitor that has been approved for stroke prophylaxis in patients
with NVAF. The risk of gastrointestinal bleeding was comparable between apixaban and
warfarin, and apixaban showed a reduction in mortality rates [6]. Apixaban was also evalu‐
ated in patients who could not take warfarin in apixaban versus acetylsalicylic acid to pre‐
vent stroke (AVERROES) trial [19]. Apixaban was more effective and as safe as aspirin in stroke
prophylaxis; thus, the study was prematurely terminated because of clear advantage of apix‐
aban. The benefits of apixaban were consistent regardless of age with a greater absolute risk
reduction in the elderly [20].
3.3. Edoxaban
Edoxaban is a factor Xa inhibitor that has been approved for stroke prophylaxis recently. It
has been tested in two different doses (30 and 60 mg) against warfarin [5]. The high dose of
edoxaban was associated with a trend toward better efficacy versus warfarin for stroke and
systemic embolism prophylaxis. A real-world modeling analysis also showed edoxaban 60 mg
od might be superior to warfarin and 30 mg od dose [21]. The efficacy of edoxaban was
decreased in patients with a creatine clearance <95 mL/min. Thus it is not recommended in
these patients.




Betrixaban is a factor Xa inhibitor with minimal renal excretion and a long half-life. It has
minimal hepatic metabolism. Thus it could be used for patients with renal and hepatic
impairment. The anticoagulant effect and safety of betrixaban were compared against warfarin
in NVAF patients in a phase II study (EXPLORE-Xa) [22]. Betrixaban was well tolerated, and
bleeding was lowest in betrixaban 40 mg group compared warfarin or betrixaban 60–80 mg.
The study was primarily designed to assess safety of betrixaban, and it does not provide an
information for the efficacy. The pharmacometric modeling suggests that 80 mg daily betrix‐
aban has comparable anticoagulant effect to warfarin. The ongoing phase III trial (APEX) is
currently investigating the protective effect of betrixaban in venous thromboembolism (VTE)
against enoxaparin in acute medically ill patients. The topline results of the study showed
betrixaban given once daily at a dose of 80 mg for 35–47 days was more effective than injectable
enoxaparin given at a dose of 40 mg for 6–14 days [23]. There was no increase in major bleeding
rates.
4. Comparison of real-world data and phase III trials
Large phase III trials showed a comparable effect and better safety profile of NOACs for stroke
thromboprophylaxis. However, these studies included highly selected patients without severe
comorbidities with strict follow-up procedures. In addition all the patients in these trials were
OAC indicated. However, observational studies showed OAC use was 60–80 % in real-world
settings [24–27]. Another concern regarding OAC therapy is the appropriate use. Inappropri‐
ate use might be up to 87 % in warfarin and 47 % in NOACs [28, 29]. The efficacy and safety
of NOACs were confirmed in observational studies. Danish registry compared the safety and
efficacy of dabigatran against warfarin [30]. Both 110 and 150 mg bid doses of dabigatran were
as effective as warfarin for stroke prophylaxis, and 110 mg bid but not 150 mg bid was
associated with lower rates of gastrointestinal bleeding. A recent meta-analysis also showed
similar stroke rates with dabigatran comparing warfarin and lower intracranial bleeding with
an elevated risk for gastrointestinal bleeding [24]. Xarelto® on prevention of stroke and non-
central nervous system systemic embolism in patients with non-valvular atrial fibrillation
(XANTUS) trial with rivaroxaban showed better efficacy and safety profile in a real-world
dataset [31]. A propensity score-matched study also showed the efficacy and safety of
rivaroxaban in real-world data [32]. These observations showed NOACs are safe and effective
treatment options for stroke prevention in NVAF patients. However, a recent real-world
database study from the USA revealed a 4.4-fold increase in the use of reduced dose of apixaban
comparing ARISTOTLE trial [33].
5. Reversal agents
One of the main difficulties with NOACs is the lack of specific reversal agents. Despite the
lower rates of hemorrhage with NOACs comparing warfarin, a hemorrhagic complication that
Anticoagulation Therapy134
needs medical support may occur with NOACs. While a minor bleeding might be solved with
supportive care, specific medications should be used for major bleedings. Perioperative
management for patients on NOAC may also be challenging especially in emergency situa‐
tions. Activated charcoal should be administered if the drug has recently been taken. Hemo‐
dialysis is an option for patients on dabigatran. Tranexamic acid and aminocaproic acid are
also nonspecific agents that can be used to control bleeding. Fresh frozen plasma is not an
option; however, prothrombin plasma concentrates (PCC) especially four-factor PCC are more
useful. However, there has been an unmet need for specific reversal agents until idarucizu‐
mab’s FDA approval. Idarucizumab is a monoclonal antibody that was approved for reversal
of dabigatran’s anticoagulant effect. Andexanet alfa is a specific antidote of factor Xa inhibitors,
and ciraparantag is a universal reversal agent.
5.1. Idarucizumab
Idarucizumab is a monoclonal antibody fragment that specifically binds to dabigatran and
antagonizes its effect at a 1:1 ratio. Its half-life is 45 min and thus it may require repeat infusion.
The effect of idarucizumab was shown by measuring dTT and ECT which are specific for
dabigatran activity. The efficacy and safety of idarucizumab were evaluated in RE-VERSE AD
(a study of the reversal effects of idarucizumab on active dabigatran) phase III trial, and a 5 g
intravenous infusion was found safe and effective [34]. In 35 patients with major bleeding,
hemostasis was restored at a median of 11.4 h, and in 36 patients who underwent urgent
procedure, normal hemostasis was reported in 33, mildly abnormal in 2, and moderately
abnormal in 1 patient. Idarucizumab was approved by FDA for the reversal of dabigatran’s
anticoagulant effect. It does not have prolonged effect, and dabigatran can be restarted after
24 h.
5.2. Andexanet alfa
Andexanet alfa is a recombinant factor Xa inhibitor antidote. It specifically binds to factor Xa
inhibitors thus reduces their unbound concentrations. It has been studied in animal and hu‐
man studies and reversed anticoagulant effect of rivaroxaban, apixaban, and edoxaban [35,
36]. The effect of andexanet alfa disappears in the absence of a maintenance infusion. Consis‐
tent with the half-life of andexanet alfa, the anticoagulant effect reversal was comparable with
placebo after 2 h cessation of infusion. Levels of D-dimer and prothrombin fragments 1 and 2
were elevated in patients receiving andexanet alfa; however, this was not associated with
clinical thrombotic events [36]. Andexanet alfa is a potential universal antidote for factor Xa
inhibitors.
5.3. Ciraparantag
Ciraparantag is a small molecule that binds unfractionated and low-molecular-weight heparin.
It binds to endogenous targets of anticoagulants that prevent their anticoagulant effect. It also
binds to dabigatran and factor Xa inhibitors; thus, it has a wide range of action. The first human
study with this drug reported effective and safe reversal of anticoagulant effect of edoxaban
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within 10–30 min [37]. Ciraparantag is a promising universal reversal agent of anticoagulant
effect.
6. Conclusion
The risk of ischemic stroke is increased in patients with AF. Recent guidelines for the evaluation
of AF recommend OAC therapy for AF patients who had moderate to high risk of stroke.
Although NOACs have clear advantages over warfarin, there are some concerns such as the
lack of specific antidote, older patients, lower creatinine clearance, risk of gastrointestinal
hemorrhage, and cost. Specific antidotes are under development—idarucizumab has already
been approved—and lower doses of the drugs might be a solution for high-bleeding-risk-
group patients. The phase III trials and real-world data indicated NOACs were as safe and
effective as warfarin, while some studies showed better net clinical benefit with NOACs. The
introduction of NOACs has led to an improvement in the management of patients with NVAF;
however, there is need for great effort for the optimization of stroke prevention strategies in
AF.
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